Healthcare
Purple Biotech Ltd.(PPBT)
Live Price
Offline$1.58
+2.60% today
1Y Change
-93.17%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- โ
- Revenue Growth
- 0.0%
- EPS Growth
- -24967.9%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Purple Biotech Ltd. (PPBT) is a Healthcare stock with listed on NASDAQ. The stock last traded around $1.58 and down 93.2% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -24967.9%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -24967.9%, free cash flow +61.4% with operating margin 0.0% and ROIC -295.3%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PPBT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 20, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -24967.9%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.6% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 20, 2026 | โ | -9.4% | -5.7% | โ |
2026 Mar 13, 2026 | -483.8% | -0.2% | -2.9% | +0.7% |
2025 Nov 14, 2025 | -11.5% | +0.3% | +6.7% | +4.6% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PPBT
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PPBT Max Drawdown
-94.45%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PPBT and SPY.
Company Overview
Purple Biotech Ltd.
NASDAQ Capital Market
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
- Leadership
- Gil Efron
- IPO Date
- Nov 20, 2015
- Employees
- 9
- Street Address
- 4 Oppenheimer Street
- Mailing
- Rehovot, 7670104
- Region
- Rehovot, IL
- Reporting Currency
- USD
- Investor Line
- 972 3 933 3121
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 1.2
- Price/Sales
- โ
- Price/Book
- 0.3
Growth
- Revenue
- 0.0%
- EPS
- -24967.9%
- Free Cash Flow
- +61.4%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -98.5%
- ROIC
- -295.3%
Balance Sheet
- Debt/Equity
- 0.03
- Current Ratio
- 1.27
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.